New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era
This study highlights the prognostic impact of co-mutations, particularly TP53, in EGFRmut NSCLC treated with osimertinib. These findings underscore the need for novel therapeutic approaches and personalized treatment strategies, especially in subgroups with poor prognoses. Trials such as MARIPOSA and FLAURA-2 provide promising evidence for treatment intensification, but careful patient stratification is essential to balance efficacy and toxicity.
Authors
- Roberto Hernández (ORCID: https://orcid.org/0009-0009-9990-4512)
- Federico Rojo (ORCID: https://orcid.org/0000-0001-9989-0290)
- Nerea Carvajal
- Maricruz Martín-Soberón
- Carlota Santolaya
- Jaime Rubio (ORCID: https://orcid.org/0000-0002-3794-9119)
- Sandra Zazo
Institutions
- Institut Gustave Roussy (FR)
- Hospital Universitario Fundación Alcorcón (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Hospital Universitario de Fuenlabrada (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100945
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00